article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

article thumbnail

Biogen strikes RNAi deal with City; Aurion withdraws IPO

BioPharma Drive: Drug Pricing

Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug. City will receive $46 million from Biogen under the alliance.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Collaboration aims to reduce animal use in drug safety testing

Broad Institute

It is already used throughout the pharmaceutical industry to discover the causes of and treatments for disease, but recently the team recognized the potential of Cell Painting, along with transcriptomic and proteomic methods, for toxicity testing.

article thumbnail

Arrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi

The Pharma Data

“Greater China has long been seen as a critical growth market in biopharma, and when we founded Visirna in 2022, we recognized that our RNAi platform had the potential to make a meaningful impact on cardiometabolic disease there,” said Christopher Anzalone, Ph.D., President and CEO of Arrowhead. “We

article thumbnail

Toxicology transformed: Why accuracy now leads the way

Drug Target Review

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

article thumbnail

Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy

The Pharma Data

Fosun Pharma is granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR, Taiwan, and select Southeast Asian countries. This collaborative framework specifies the respective responsibilities for each party.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

NGS has revolutionised genomic analysis, enabling the identification of disease-related genetic variants. This ability to correlate seemingly disparate data is crucial for tackling complex targets and discovering new treatments for diseases considered difficult to treat with conventional approaches.